EXAS241115C77500
- 1.85
- -0.20-9.76%
Exact Sciences Newsroom
Will Screening Sales Drive Exact Sciences' Q3 Earnings?
Exact Sciences Corporation (EXAS) Bounced Back in Q3
Humacyte's $30 Million Stock Offering Fuels Growth Despite Insider Concerns
Exact Sciences Corp (EXAS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ...
(EXAS) - Analyzing Exact Sciences's Short Interest
Exact Sciences Schedules Third Quarter 2024 Earnings Call
BTIG Maintains Exact Sciences(EXAS.US) With Buy Rating, Maintains Target Price $82
Buy Rating on Exact Sciences: Anticipating Growth From Cologuard Plus and Strategic Initiatives
Leerink Partners Maintains Exact Sciences(EXAS.US) With Buy Rating, Announces Target Price $100
Sector Update: Health Care Stocks Rise Pre-Bell Friday
Express News | Exact Sciences Shares up 1.2% Premarket After FDA Approves Co's Colorectal Cancer Screening Test
Express News | Exact Sciences Corp - Cologuard Plus Test Expected to Launch With Medicare Coverage in 2025
Express News | FDA Approves Exact Sciences’ Cologuard Plus Test, Setting a New Benchmark in Non-Invasive Colorectal Cancer Screening
FDA Approves Exact Sciences' Cologuard Plus Test, Setting a New Benchmark in Non-Invasive Colorectal Cancer Screening
Exact Sciences Corporation's (NASDAQ:EXAS) Path To Profitability
Evercore Maintains Exact Sciences(EXAS.US) With Buy Rating, Raises Target Price to $80
Exact Sciences Price Target Raised to $80 From $72 at Evercore ISI
Trending Stocks Today | ZK International Soars 50.55% Post-Market
Leerink Partners Maintains Exact Sciences(EXAS.US) With Buy Rating
Buy Rating for Exact Sciences as Cologuard Plus Poised for Growth and Upside Pricing Potential